Patents by Inventor Shani Leviatan

Shani Leviatan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220031720
    Abstract: The present invention provides an active cancer vaccine and specifically an immunogenic compositions of membrane vesicles that serve as biomimetic nanoparticles derived from eukaryotic cell membranes that bear N-glycolylneuraminic acid glycoconjugates. These compositions can elicit beneficial immunological responses for treatment of Neu5Gc-positive tumors. The present invention provides methods of generating and using Neu5Gc-conjugated nanoparticles from eukaryotic cells membranes designated nano-ghosts.
    Type: Application
    Filed: November 21, 2019
    Publication date: February 3, 2022
    Inventors: Vered PADLER-KARAVANI, Eliran Moshe REUVEN, Shani LEVIATAN BEN-ARYE
  • Patent number: 7989183
    Abstract: A soluble fusion protein is disclosed. The soluble fusion protein comprises at least one soluble polypeptide and a heterologous polypeptide being fused thereto, the heterologous polypeptide being normally insoluble and/or suboptimally expressed when expressed in a cell, wherein the at least one soluble polypeptide has an amino acid sequence at least 65 percent similar to SEQ ID NO: 1 and/or 2, as determined using the Standard protein-protein BLAST [blastp] software of the NCBI.
    Type: Grant
    Filed: March 2, 2009
    Date of Patent: August 2, 2011
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Nathan Nelson, Anat Lavi-Itzkovitz, Shani Leviatan
  • Publication number: 20090226970
    Abstract: A soluble fusion protein is disclosed. The soluble fusion protein comprises at least one soluble polypeptide and a heterologous polypeptide being fused thereto, the heterologous polypeptide being normally insoluble and/or suboptimally expressed when expressed in a cell, wherein the at least one soluble polypeptide has an amino acid sequence at least 65 percent similar to SEQ ID NO: 1 and/or 2, as determined using the Standard protein-protein BLAST [blastp] software of the NCBI.
    Type: Application
    Filed: March 2, 2009
    Publication date: September 10, 2009
    Applicant: Ramot At Tel Aviv University Ltd.
    Inventors: Nathan Nelson, Anat Lavi-Itzkovitz, Shani Leviatan
  • Patent number: 7560250
    Abstract: A soluble fusion protein is disclosed. The soluble fusion protein comprises at least one soluble polypeptide and a heterologous polypeptide being fused thereto, the heterologous polypeptide being normally insoluble and/or suboptimally expressed when expressed in a cell, wherein the at least one soluble polypeptide has an amino acid sequence at least 65 percent similar to SEQ ID NO: 1 and/or 2, as determined using the Standard protein-protein BLAST [blastp] software of the NCBI.
    Type: Grant
    Filed: February 12, 2007
    Date of Patent: July 14, 2009
    Assignee: Ramot At Tel Aviv University Ltd.
    Inventors: Nathan Nelson, Anat Lavi, Shani Leviatan
  • Publication number: 20070202573
    Abstract: A soluble fusion protein is disclosed. The soluble fusion protein comprises at least one soluble polypeptide and a heterologous polypeptide being fused thereto, the heterologous polypeptide being normally insoluble and/or suboptimally expressed when expressed in a cell, wherein the at least one soluble polypeptide has an amino acid sequence at least 65 percent similar to SEQ ID NO: 1 and/or 2, as determined using the Standard protein-protein BLAST [blastp] software of the NCBI.
    Type: Application
    Filed: February 12, 2007
    Publication date: August 30, 2007
    Applicant: Ramot At Tel Aviv University Ltd.
    Inventors: Nathan Nelson, Anat Lavi, Shani Leviatan